论文部分内容阅读
随着中国经济实力的飞速发展,中国企业的国际化进程不断加快,越来越多的中国企业选择以并购的方式对外直接投资。为了拓展海外市场,扩大竞争优势,许多中国医药企业,也选择了海外并购的道路。然而很多中国医药企业的海外并购之旅并非坦途,知识产权是并购中的非常重要的议题,但是并购中的知识产权问题却屡见不鲜,例如知识产权价值评估不当、知识产权权利存在瑕疵、知识产权所涉及的技术先进程度不高、知识产权科技成果转化率低、知识产权后期管理不利,严重妨碍了中国医药企业海外并购后的健康发展。因此,提出几方面解决问题的建议,包括正视医药知识产权保护的地域差异性、合理评估知识产权所保护的医药技术含金量和市场价值、重视医药知识产权的相关联性及布局。
With the rapid development of China’s economy, the internationalization of Chinese enterprises is accelerating. More and more Chinese enterprises choose to direct foreign investment through mergers and acquisitions. In order to expand overseas markets and expand their competitive advantages, many Chinese pharmaceutical companies have also chosen the path of overseas mergers and acquisitions. However, the journey of overseas M & A for many Chinese pharmaceutical companies is not a smooth one. Intellectual property is a very important issue in mergers and acquisitions. However, the intellectual property issues in mergers and acquisitions are not uncommon. For example, improper evaluation of the value of intellectual property, flaws in intellectual property rights, The low degree of technological advance involved, the low conversion rate of scientific and technological achievements in intellectual property and the unfavorable management of late intellectual property rights have seriously hindered the healthy development of Chinese pharmaceutical enterprises after their overseas mergers and acquisitions. Therefore, some suggestions on how to solve the problems are put forward. These include: addressing the regional differences in the protection of pharmaceutical intellectual property rights; properly assessing the gold content and market value of pharmaceutical technologies protected by intellectual property rights; and emphasizing the relevance and distribution of pharmaceutical intellectual property rights.